| [1] |
Zhang L, Dong Q, Wang Y, Li X, Li C, et al. 2025. Global trends and risk factors in gastric cancer: a comprehensive analysis of the Global Burden of Disease Study 2021 and multi-omics data. |
| [2] |
Guan WL, He Y, Xu RH. 2023. Gastric cancer treatment: recent progress and future perspectives. |
| [3] |
Yan C, Shan F, Ying X, Li Z. 2023. Global burden prediction of gastric cancer during demographic transition from 2020 to 2040. |
| [4] |
Kong W, Wang Z, Wang B. 2023. Unveiling DNA damage repair-based molecular subtypes, tumor microenvironment and pharmacogenomic landscape in gastric cancer. |
| [5] |
Zhao Z, Mak TK, Shi Y, Huang H, Huo M, et al. 2023. The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer. |
| [6] |
Yang E, Chua W, Ng W, Roberts TL. 2021. Peripheral cytokine levels as a prognostic indicator in gastric cancer: a review of existing literature. |
| [7] |
Jiang Y, Wang Y, Chen G, Sun F, Wu Q, et al. 2024. Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. |
| [8] |
Lo YH, Kolahi KS, Du Y, Chang CY, Krokhotin A, et al. 2021. A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and nonessential modes of oncogenic transformation. |
| [9] |
Zhu Y, Zhou B, Hu X, Ying S, Zhou Q, et al. 2022. LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. |
| [10] |
The Cancer Genome Atlas Research Network. 2014. Comprehensive molecular characterization of gastric adenocarcinoma. |
| [11] |
Langfelder P, Horvath S. 2008. WGCNA: an R package for weighted correlation network analysis. |
| [12] |
Zhang B, Horvath S. 2005. A general framework for weighted gene co-expression network analysis. |
| [13] |
Inoue K, Dewar K, Katsanis N, Reiter LT, Lander ES, et al. 2001. The 1.4-Mb CMT1A duplication/HNPP deletion genomic region reveals unique genome architectural features and provides insights into the recent evolution of new genes. |
| [14] |
Yu T, Zhang T, Zhao L, Li K, Li J, et al. 2023. Bioinformatic analysis the expression and clinical significance of CDRT15 in cholangiocarcinoma using TCGA database. |
| [15] |
Xu Q, Liu C, Wang H, Li S, Yan H, et al. 2024. Deciphering the impact of aggregated autophagy-related genes TUBA1B and HSP90AA1 on colorectal cancer evolution: a single-cell sequencing study of the tumor microenvironment. |
| [16] |
Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, et al. 2018. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. |
| [17] |
Karagkouni D, Paraskevopoulou MD, Chatzopoulos S, Vlachos IS, Tastsoglou S, et al. 2018. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions. |
| [18] |
Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, et al. 2016. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. |
| [19] |
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, et al. 2009. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. |
| [20] |
Rawla P, Barsouk A. 2019. Epidemiology of gastric cancer: global trends, risk factors and prevention. |
| [21] |
Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, et al. 2013. Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience. |
| [22] |
Wang J, Wu Z, de Groot EM, Challine A, Mohammad NH, et al. 2024. Discontinuation of neoadjuvant therapy does not influence postoperative short-term outcomes in elderly patients (≥ 70 years) with resectable gastric cancer: a population-based study from the dutch upper gastrointestinal cancer audit (DUCA) data. |
| [23] |
Arkenau HT, Saggese M, Lemech C. 2012. Advanced gastric cancer: is there enough evidence to call second-line therapy standard? |
| [24] |
Shin HB, An JY, Lee SH, Choi YY, Kim JW, et al. 2017. Is adjuvant chemotherapy necessary in pT1N1 gastric cancer? |
| [25] |
Christodoulidis G, Koumarelas KE, Kouliou MN. 2024. Revolutionizing gastric cancer treatment: the potential of immunotherapy. |
| [26] |
Zhou J, Ji Q, Li Q. 2021. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. |
| [27] |
Chen DS, Mellman I. 2017. Elements of cancer immunity and the cancer–immune set point. |
| [28] |
Li YN, Xie B, Zhang Y, He MH, Xing Y, et al. 2023. Advances and key focus areas in gastric cancer immunotherapy: a comprehensive scientometric and clinical trial review (1999−2023). |
| [29] |
Wang Q, Tan W, Zhang Z, Chen Q, Xie Z, et al. 2024. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma. |
| [30] |
Zhang J, Dong Y, Yu S, Hu K, Zhang L, et al. 2024. IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages. |
| [31] |
Wang B, Gu B, Gao L, Ma C, Li X, et al. 2025. SERPINE1 facilitates metastasis in gastric cancer through anoikis resistance and tumor microenvironment remodeling. |
| [32] |
Huang H, Zhou J, Chen H, Li J, Zhang C, et al. 2021. The immunomodulatory effects of endocrine therapy in breast cancer. |
| [33] |
Przemeck SMC, Varro A, Berry D, Steele I, Wang TC, et al. 2008. Hypergastrinemia increases gastric epithelial susceptibility to apoptosis. |